Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 12/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280552 | 0.88 | PTGDR2 (0.50) | PTGDR2FFAR1PPARDTHRATHRB | |
| Benzene SCHEMBL2280559 | 0.87 | PTGDR2 (0.48) | PTGDR2FFAR1PPARDTHRATHRB | |
| SCHEMBL2285921 | 0.86 | PTGDR2 (0.45) | PTGDR2FFAR1PPARDTHRATHRB | |
| SCHEMBL2286048 | 0.85 | PTGDR2 (0.47) | PTGDR2FFAR1PPARDTHRATHRB | |
| SCHEMBL2282112 | 0.83 | PTGDR2 (0.43) | PTGDR2FFAR1PPARDTHRATHRB | |
| SCHEMBL2282723 | 0.82 | PTGDR2 (0.41) | PTGDR2FFAR1PPARDTHRATHRB | |
| SCHEMBL2277977 | 0.82 | PPARD (0.49) | PTGDR2FFAR1PPARDTHRATHRB | |
| SCHEMBL12409417 | 0.81 | PTGDR2 (0.43) | PTGDR2FFAR1PPARDTHRATHRB | |
| SCHEMBL2280428 | 0.81 | PTGDR2 (0.41) | PTGDR2PPARDTHRATHRB | |
| SCHEMBL2280539 | 0.81 | PTGDR2 (0.43) | PTGDR2PPARDNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | claimed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | AMIRA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003127-A2 | ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS | AMIRA PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190227-A1 | Antagonists of Prostaglandin D2 Receptors | PTGDR, PTGDR2, PTGER2 | PTGDR2 2/4885FFAR1 149/4885PPARD 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.